International Scholarly Research Notices

Research Article

Endothelin-1 Levels in Scleroderma Patients: A Pilot Study

Table 1

Correlation between clinical subsets (DfSSC, LcSSc, CREST, and overlap syndrome), presence of ulcers, serological data (ANA, anti-ENA, and ET-1 concentrations), and different treatments (CA, bosentan).


Patient	DUs	Therapy	Anticentromere		Anti-ENA		ET-1 concentration (pg/mL)
Patient	DUs	Therapy	1° serum	2° serum	1° serum	2° serum	1° serum	2° serum

(1) DfSSc, PAH	Yes	Bosentan	Neg.	Neg.	Scl 70 (127,2)	Scl 70 (130,8)	8,1	6,9
(2) DfSSc	No	CA	Neg.	Neg.	Scl 70 (46,9); SS-A (143)	Scl 70 (75,0); SS-A (143,8)	7,3	3,7
(3) LcSSc,	Yes	CA	Neg.	Neg.	Neg.	Neg.	4,6	4,6
(4) LcSSc, PAH	No	Bosentan	Pos.	Pos.	Neg.	Neg.	5,7	4,6
(5) LcSSc, PAH	Yes	Bosentan	Pos.	Pos.	Neg.	Neg.	4,8	3,7
(6) LcSSc	No	CA	Neg.	Neg.	Scl 70 (108,8)	Scl 70 (136,6)	4,6	4,4
(7) LcSSc, PAH	No	Bosentan	Pos.	Pos.	Neg.	Neg.	3,8	3,5
(8) LcSSc	Yes	CA	Neg.	Neg.	SS-A (132,1)	SS-A (133,5)	24	4,1
(9) LcSSc, PAH	No	Bosentan	Pos.	Pos.	Neg.	Neg.	6,0	4,9
(10) LcSSc	Yes	CA	Pos.	Pos.	Neg.	Neg.	4,35	4,6
(11) LcSSc	No	CA	Pos.	Pos.	SS-A (33,0)	SS-A (43,8)	5,0	4,6
(12) LcSSc	Yes	CA	Pos.	Pos.	Neg.	Neg.	4,2	4,2
(13) LcSSc	Yes	CA	Pos.	Pos.	Neg.	Neg.	4,0	3,6
(14) LcSSc	No	CA	Neg.	Neg.	Neg.	Neg.	4,0	3,7
(15) LcSSc	No	CA	Pos.	Pos.	Neg.	Neg.	4,3	3,75
(16) LcSSc	No	CA	Neg.	Neg.	Scl 70 (133,4); SS-A (41,4)	Scl 70 (134,0); SS-A (44,6)	3,3	4,5
(17) CREST	No	CA	Pos.	Pos.	Neg.	Neg.	4,3	3,2
(18) DfSSc	No	CA	Neg.	Neg.	Scl 70 (102,3); SS-A (128,1); SS-B (127,1)	Scl 70 (121,0); SS-A (133,8); SS-B (131,0)	6,4	7,2

DfSSc: diffuse scleroderma; LcSSc: limited scleroderma; PAH: pulmonary arterial hypertension; DUs: digital ulcers; ANA: anti-nuclear antibodies; anticentromere: anticentromere antibodies; anti-ENA (Scl 70, SS-A, SS-B): anti-extractable nuclear antigen antibodies; ET-1: endothelin-1; Neg.: negative; Pos.: positive.